FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2002910367> ?p ?o ?g. }

• W2002910367 endingPage "3222" @default.
• W2002910367 startingPage "3216" @default.
• W2002910367 abstract "Palifermin, a recombinant human keratinocyte growth factor, was tested for potential benefits on acute graft-versus-host disease (GVHD) and hematopoietic recovery in allogeneic hematopoietic stem cell transplantation (HSCT) recipients. This randomized, double-blind, placebo-controlled, dose-escalation study assessed the safety and tolerability of palifermin (n = 69) as compared with placebo (n = 31) in patients conditioned with cyclophosphamide and fractionated total-body irradiation (Cy/TBI) or busulfan and cyclophosphamide (Bu/Cy) and given methotrexate along with a calcineurin inhibitor (cyclosporine A, tacrolimus) for GVHD prophylaxis. All patients received 3 doses before conditioning and either 3 (cohort 1), 6 (cohort 2), or 9 (cohort 3) doses after HSCT. Palifermin doses were 40 μg/kg per day (cohort 1 only) or 60 μg/kg per day (all cohorts). Six patients (placebo = 2, palifermin = 4) experienced a total of 11 dose-limiting toxicities (most often skin, respiratory, or oral mucositis). The most common adverse events included edema, infection, skin pain, or rash. Times to neutrophil and platelet engraftment were similar. No significant differences in acute GVHD incidence or severity, survival, or day 100 relapse rates were observed between groups. Palifermin was associated with reduced incidence and mean severity of mucositis in patients conditioned with Cy/TBI but not Bu/Cy. We conclude that palifermin was generally safe in allogeneic HSCTs but had no significant effect on engraftment, acute GVHD, or survival in this trial." @default.
• W2002910367 created "2016-06-24" @default.
• W2002910367 creator A5011726019 @default.
• W2002910367 creator A5023099227 @default.
• W2002910367 creator A5030368112 @default.
• W2002910367 creator A5058268746 @default.
• W2002910367 creator A5070132319 @default.
• W2002910367 creator A5072614870 @default.
• W2002910367 creator A5080104357 @default.
• W2002910367 date "2006-11-01" @default.
• W2002910367 modified "2023-10-18" @default.
• W2002910367 title "Phase 1/2 randomized, placebo-control trial of palifermin to prevent graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT)" @default.
• W2002910367 cites W116285681 @default.
• W2002910367 cites W1274344746 @default.
• W2002910367 cites W1491993932 @default.
• W2002910367 cites W1493614585 @default.
• W2002910367 cites W1515588499 @default.
• W2002910367 cites W1581519755 @default.
• W2002910367 cites W1795844187 @default.
• W2002910367 cites W1980927128 @default.
• W2002910367 cites W2031139135 @default.
• W2002910367 cites W2032156551 @default.
• W2002910367 cites W2046687522 @default.
• W2002910367 cites W2054405406 @default.
• W2002910367 cites W2060409188 @default.
• W2002910367 cites W2064411005 @default.
• W2002910367 cites W2071927386 @default.
• W2002910367 cites W2073292917 @default.
• W2002910367 cites W2076937813 @default.
• W2002910367 cites W2080716137 @default.
• W2002910367 cites W2094292853 @default.
• W2002910367 cites W2110493040 @default.
• W2002910367 cites W2115339597 @default.
• W2002910367 cites W2130415182 @default.
• W2002910367 cites W2144897379 @default.
• W2002910367 cites W2145479510 @default.
• W2002910367 cites W2149168996 @default.
• W2002910367 cites W2150776396 @default.
• W2002910367 cites W2151588959 @default.
• W2002910367 cites W2154101238 @default.
• W2002910367 cites W2154579075 @default.
• W2002910367 cites W2160115655 @default.
• W2002910367 cites W2171009770 @default.
• W2002910367 cites W2553826972 @default.
• W2002910367 cites W2576986565 @default.
• W2002910367 cites W3134201403 @default.
• W2002910367 cites W70404253 @default.
• W2002910367 doi "https://doi.org/10.1182/blood-2006-04-017780" @default.
• W2002910367 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1895527" @default.
• W2002910367 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16835378" @default.
• W2002910367 hasPublicationYear "2006" @default.
• W2002910367 type Work @default.
• W2002910367 sameAs 2002910367 @default.
• W2002910367 citedByCount "133" @default.
• W2002910367 countsByYear W20029103672012 @default.
• W2002910367 countsByYear W20029103672013 @default.
• W2002910367 countsByYear W20029103672014 @default.
• W2002910367 countsByYear W20029103672015 @default.
• W2002910367 countsByYear W20029103672016 @default.
• W2002910367 countsByYear W20029103672017 @default.
• W2002910367 countsByYear W20029103672018 @default.
• W2002910367 countsByYear W20029103672019 @default.
• W2002910367 countsByYear W20029103672020 @default.
• W2002910367 countsByYear W20029103672021 @default.
• W2002910367 countsByYear W20029103672022 @default.
• W2002910367 countsByYear W20029103672023 @default.
• W2002910367 crossrefType "journal-article" @default.
• W2002910367 hasAuthorship W2002910367A5011726019 @default.
• W2002910367 hasAuthorship W2002910367A5023099227 @default.
• W2002910367 hasAuthorship W2002910367A5030368112 @default.
• W2002910367 hasAuthorship W2002910367A5058268746 @default.
• W2002910367 hasAuthorship W2002910367A5070132319 @default.
• W2002910367 hasAuthorship W2002910367A5072614870 @default.
• W2002910367 hasAuthorship W2002910367A5080104357 @default.
• W2002910367 hasBestOaLocation W20029103672 @default.
• W2002910367 hasConcept C126322002 @default.
• W2002910367 hasConcept C141071460 @default.
• W2002910367 hasConcept C142724271 @default.
• W2002910367 hasConcept C168563851 @default.
• W2002910367 hasConcept C203014093 @default.
• W2002910367 hasConcept C204787440 @default.
• W2002910367 hasConcept C27081682 @default.
• W2002910367 hasConcept C2777408962 @default.
• W2002910367 hasConcept C2779134260 @default.
• W2002910367 hasConcept C2779972918 @default.
• W2002910367 hasConcept C28328180 @default.
• W2002910367 hasConcept C2911091166 @default.
• W2002910367 hasConcept C54355233 @default.
• W2002910367 hasConcept C71924100 @default.
• W2002910367 hasConcept C86803240 @default.
• W2002910367 hasConceptScore W2002910367C126322002 @default.
• W2002910367 hasConceptScore W2002910367C141071460 @default.
• W2002910367 hasConceptScore W2002910367C142724271 @default.
• W2002910367 hasConceptScore W2002910367C168563851 @default.
• W2002910367 hasConceptScore W2002910367C203014093 @default.
• W2002910367 hasConceptScore W2002910367C204787440 @default.
• W2002910367 hasConceptScore W2002910367C27081682 @default.
• W2002910367 hasConceptScore W2002910367C2777408962 @default.

• next